Boston Scientific (NYSE:BSX) Director David Habiger Buys 2,200 Shares

21 May 2026, 19:58 by Jessica Moore · The Cerbat Gem

Boston Scientific Corporation (NYSE:BSX – Get Free Report) Director David Habiger bought 2,200 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average price of $56.95 per share, for a total transaction of $125,290.00. Following the completion of the transaction, the director owned 11,628 shares of the company’s stock, valued at $662,214.60. This represents a 23.33% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Boston Scientific Price Performance

BSX traded up $0.41 during trading on Thursday, reaching $57.08. 12,837,051 shares of the stock were exchanged, compared to its average volume of 16,615,801. The business’s 50 day moving average price is $62.46 and its two-hundred day moving average price is $80.71. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market capitalization of $84.84 billion, a price-to-earnings ratio of 23.88, a P/E/G ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a 1 year low of $52.52 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in the business. Claret Asset Management Corp lifted its position in Boston Scientific by 4.4% during the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after buying an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC lifted its position in Boston Scientific by 5.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after buying an additional 103 shares during the period. Outfitters Financial LLC lifted its position in Boston Scientific by 0.5% during the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after buying an additional 110 shares during the period. Fayez Sarofim & Co lifted its position in Boston Scientific by 2.1% during the third quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after buying an additional 111 shares during the period. Finally, Natural Investments LLC lifted its position in Boston Scientific by 2.9% during the fourth quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after buying an additional 112 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BSX. National Bank Financial set a $115.00 price objective on Boston Scientific in a research report on Monday, February 2nd. Truist Financial reduced their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Needham & Company LLC restated a “buy” rating and issued a $77.00 price objective on shares of Boston Scientific in a research report on Monday. Finally, Wells Fargo & Company reduced their price objective on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a research report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $92.71.

Check Out Our Latest Analysis on Boston Scientific

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Insider purchases are often viewed as a sign of management confidence in the company’s outlook and can support sentiment around the stock.
Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. The FRACTURE trial met all primary safety and effectiveness endpoints, which strengthens the case for a future regulatory submission and supports the company’s growth story in interventional cardiology.
Neutral Sentiment: Baird kept an Outperform rating on Boston Scientific, though it trimmed its price target to $75 from $78. That suggests the firm still sees upside, but the lower target may temper enthusiasm somewhat.
Negative Sentiment: Recent commentary also pointed to Boston Scientific having fallen on weak results, and the stock remains well below its longer-term moving averages. That indicates investors are still weighing execution concerns and broader pressure on the shares despite the upbeat insider and clinical developments.

About Boston Scientific

(Get Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.